Ann: Reminder of Investor Webinar - NanaBis Phase III Trial, page-8

Yes it seems MXC @ $140MILL & CPH $210MILL are better investment opportunities than Medlab's cannabis phase 3 trial @$70mill. Nothing exciting here for Medlab's cannabis offering compared to other cannabis stocks in the world at present. @$70mill value it assumes Medlab has nothing special to offer and its trials are not world standard like the others mentioned above. So perhaps fair value for Medlab's phase 3 is in the range of $40mill-$70mill range until the world wakes up. Until then investment interest is shying away from Medlab as evident in the past few months sell down from 0.40c to today's 0.20c. A whopping 50% decrease is shareholder value in a matter of months. While the other cannabis stocks climb to new heights with better trials and product offerings. One can only compare market caps to determine which company is a better investment.

If Medlab's current cannabis trial work was on LSE or Nasdaq would it be higher than current AUS$ value?